Heming Li | Molecular Biology | Research Excellence Award

Published on 28/11/2025 by Medical Lab Scientist

Dr. Heming Li | Molecular Biology | Research Excellence Award

Doctor | The first hospital of China Medical University | China

Dr. Heming Li is an oncology clinician-scientist whose research has generated 1,045 citations across 37 scientific documents with an h-index of 17, reflecting a sustained impact on translational cancer science. His work centers on liquid biopsy innovations, particularly circulating tumor cells (CTCs), tumor invasion and metastasis, and immunotherapy biomarkers in lung, gastric, and hepatobiliary cancers. Dr. Li is recognized for pioneering one of China’s earliest and most sensitive cell-surface vimentin (CSV)–based CTC detection platforms, integrating negative and positive enrichment to enhance diagnostic accuracy, reduce costs, and enable real-time monitoring of tumor evolution. His research spans EMT regulation, immune escape, metabolic reprogramming, and multi-omics characterization of metastatic pathways, leading to first-author and corresponding-author publications in high-impact journals such as The Lancet, Journal of Hematology & Oncology, Journal of Experimental & Clinical Cancer Research, Molecular Cancer, Cancer Letters, and Cell Death & Disease. He has elucidated mechanisms including IGF-IR signaling, KDM4A/STAT3-driven tumor progression, ICAM-1-mediated microenvironmental adaptation, and PD-L1 expression on CSV⁺ CTCs as a prognostic marker in gastric cancer. His recent studies have also advanced understanding of FGL1 as an immune checkpoint target and the biological significance of TROP2 in cancer therapeutics. As principal investigator, he has secured major national and provincial funding, including NSFC General and Young Programs, to study CTC-based biomarkers, immunotherapy prediction models, and metastasis-driving pathways. Through sustained contributions across liquid biopsy technology, molecular oncology, and clinically actionable biomarker development, Dr. Li has established a leading research profile shaping the future of precision cancer care.

Profile: Scopus

Featured Publications

1. Li, H., Yan, J., & Han, T. (2024). Combination strategies in advanced hepatocellular carcinoma: The CARES-310 trial. The Lancet, 404, 1403–1404.

2. Li, H., Zhu, Y., Xu, L., Han, T., Luan, J., Li, X., Liu, Y., Wang, Z., Liu, Q., Kong, X., Zou, C., Su, L., Hou, Y., Chen, X., Chen, L., Wang, R., Xu, Z., & Zhao, M. (2024). Cell surface vimentin as an emerging marker for CTCs and therapeutic target in advanced gastric cancer. Journal of Experimental & Clinical Cancer Research, 43, 129.

3. Qian, W., Zhao, M., Wang, R., & Li, H. (2021). Fibrinogen-like protein 1 (FGL1): The next immune checkpoint target. Journal of Hematology & Oncology, 14, 147.

4. Liu, M., Wang, R., Sun, X., Liu, Y., Wang, Z., Yan, J., Sun, M., & Li, H. (2020). PD-L1 expression on CSV⁺ CTCs predicts prognosis in gastric cancer. Molecular Oncology, 14, 865–881.

5. Li, H., Batth, I. S., Qu, X., Xu, L., Song, N., Wang, R., & Liu, Y. (2017). IGF-IR signaling in EMT and therapeutic targeting. Molecular Cancer, 16, 6.

Ding Wen Wu | Transfusion Medicine | Best Researcher Award

Published on 08/10/202508/10/2025 by Medical Lab Scientist

Prof. Ding Wen Wu | Transfusion Medicine | Best Researcher Award

Professor | NYU Grossman School of Medicine | United states

Prof. Ding Wen Wu is a distinguished researcher and educator in the field of transfusion medicine, currently affiliated with the NYU Grossman School of Medicine, United States. With a career dedicated to advancing patient blood management and diagnostic innovation, he has made notable contributions that bridge laboratory research and real-world clinical practice. His research focuses on improving transfusion safety, optimizing resource utilization, and promoting evidence-based approaches that enhance healthcare efficiency and patient outcomes. Prof. Wu’s academic profile demonstrates strong scholarly impact, with 10 published scientific documents, 97 citations, and an h-index of 3, reflecting the quality and growing influence of his work within the international medical community. His studies have appeared in highly respected journals such as JAMA Internal Medicine, Life, Healthcare, and the Journal of Clinical Apheresis, where his findings have shaped new perspectives in transfusion medicine and clinical diagnostics. Beyond research, Prof. Wu is also recognized for his mentorship and leadership in education, actively guiding emerging medical scientists and fostering collaboration, innovation, and integrity in research. His interdisciplinary approach and commitment to continuous improvement underscore his vision for integrating artificial intelligence, real-world data analytics, and precision-based methodologies into modern healthcare systems. Through his dedication to advancing transfusion science and promoting global standards in laboratory medicine, Prof. Ding Wen Wu continues to serve as an inspiring figure whose work contributes significantly to safer, more efficient, and patient-centered medical practices worldwide.

Profiles: Scopus | ORCID

Feaured Publications

1. Wu, D. W., Friedman, M. T., Lombardi, D. P., Hwang, R., Sender, J., Cobaj, V., Karpinos, R. (2024). Impact of patient blood management on red blood cell utilization in an urban community teaching hospital: A seven-year retrospective study. Life, 14(2), 232.

2. Karpinos, R., Friedman, M., Lombardi, D., Li, Y., Cobaj, V., Niazi, M., Lai, P., & Wu, D. W. (2025). Implementation and impact of a patient blood management program in an urban community hospital: An eight-year study. Healthcare, 13(19), 2462.

3. Tanhehco, Y. C., Alsammak, M., Wu, D. W., Costa, V., Chhibber, V., Levenbrown, Y., … Wehrli, G. (2024). An annual review of important apheresis articles from the American Society for Apheresis Attending Physician Subcommittee. Journal of Clinical Apheresis, 39(6), e22152.

4. Wu, D. W., Jacobson, J., Lifshitz, M., Li, Y., Lyu, C., Friedmann, R., … Hilbert, T. (2023). Association between post-transfusion hemoglobin S levels and pre-transfusion levels at the next scheduled transfusion. Journal of Clinical Apheresis, 38(5), 529–539.

5. Ortigoza, M. B., Yoon, H., Goldfeld, K. S., Troxel, A. B., Daily, J. P., Wu, Y., … Wu, D. W. (2022). Efficacy and safety of COVID-19 convalescent plasma in hospitalized patients: A randomized clinical trial. JAMA Internal Medicine, 182(2), 115–126.

Liying Ren | Molecular Biology | Best Researcher Award

Published on 13/09/202513/09/2025 by Medical Lab Scientist

Dr. Liying Ren | Molecular Biology | Best Researcher Award

Liying Ren | Peking University |China

Ren Liying is a medical researcher in hepatology and oncology, currently pursuing her Ph.D. in Internal Medicine at the Peking University Hepatology Institute, Peking University People’s Hospital, under the mentorship of Professor Chen Hongsong. She earned her Bachelor’s degree in Clinical Medicine from Hubei University of Science and Technology and her Master’s degree from Guilin Medical University under Professor Liao Weijia, before advancing to doctoral studies. Her research focuses on hepatocellular carcinoma (HCC), with an emphasis on integrating molecular biology, imaging, and clinical practice to improve patient outcomes. Ren has authored and co-authored several impactful publications in respected journals, including Cancers, Journal of Hepatocellular Carcinoma, BMC Cancer, World Journal of Gastroenterology, and Cancer Medicine. As first author, her study in Cancers identified the tumor-suppressive role of hemopexin in HCC via TNF-α–mediated mitochondrial apoptosis, while her review explored radiomics and radiogenomics as tools to bridge imaging and molecular characterization in liver cancer. She has also contributed to predictive models and radiomics-based approaches for recurrence and prognosis stratification after surgical resection of HCC. With a strong clinical foundation and commitment to translational research, Ren represents a new generation of physician-scientists advancing precision medicine in liver disease and cancer.

profile: Google scholar

Featured Publications

1.Ren L#, Man Y#, Zhang X, Guo Q, She S, Yang Y, Fei R, Cong X, Chen D, Wei W, Chen H*.**
Hemopexin Suppresses Hepatocellular Carcinoma via TNF-α-Mediated Mitochondrial Apoptosis.
Cancers. 2025; 17(18):2969. (Q2, IF=4.4)

2.Ren L#, Chen DB#, Yan X, She S, Yang Y, Zhang X, Liao W, Chen H.**
Bridging the Gap Between Imaging and Molecular Characterization: Current Understanding of Radiomics and Radiogenomics in Hepatocellular Carcinoma. Journal of Hepatocellular Carcinoma. 2024; 11:2359-2372. (Q2, IF=3.4)

3.Ren L#, Chen D#, Xu W, Xu T, Wei R, Suo L, Huang Y, Chen H, Liao W.**
Predictive Potential of Nomogram Based on GMWG for Patients with Hepatocellular Carcinoma after Radical Resection. BMC Cancer. 2021; 21(1):817. (Q2, IF=3.4)

4.Li S#, Su L#, Xu T#, Ren L#, et al.
Radiomics Model Based on Contrast-Enhanced CT to Predict Early Recurrence in Patients with Hepatocellular Carcinoma after Radical Resection. World Journal of Gastroenterology. 2023; 29(26):4186-4199. (Q1, IF=5.1)

5.Xu T#, Ren L#, Liao M#, Zhao B, Wei R, Zhou Z, He Y, Zhang H, Chen D, Chen H, Liao W.**
Preoperative Radiomics Analysis of Contrast-Enhanced CT for Microvascular Invasion and Prognosis Stratification in Hepatocellular Carcinoma. Journal of Hepatocellular Carcinoma. 2022; 9:189-201. (Q2, IF=3.4)

6.Chen D#, Gao J#, Ren L#, Chen P, Yang Y, She S, Xie Y, Liao W, Chen H.*
A Signature Based on NKG2D Ligands to Predict the Recurrence of Hepatocellular Carcinoma after Radical Resection.
Cancer Medicine. 2023; 12(5):6337-6347. (Q2, IF=3.1)

Heming Li | Molecular Biology | Research Excellence Award

Dr. Heming Li | Molecular Biology | Research Excellence Award

Featured Publications

Ding Wen Wu | Transfusion Medicine | Best Researcher Award

Prof. Ding Wen Wu | Transfusion Medicine | Best Researcher Award

Feaured Publications

Liying Ren | Molecular Biology | Best Researcher Award

Dr. Liying Ren | Molecular Biology | Best Researcher Award

Featured Publications

RECOMMENDED

Mail us